Loading...
Please wait, while we are loading the content...
Similar Documents
[Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review.].
| Content Provider | Semantic Scholar |
|---|---|
| Author | Yao, Nan Jiang, Lei Yang, Kehu Ye, Yancheng Mi, Denghai Min, Guangtao |
| Copyright Year | 2009 |
| Abstract | BACKGROUND It is unclear whether etoposide/cisplatin (EP) regimen is the optimal chemotherapy regimen in the treatment patients with extensive small cell lung cancer (SCLC), this study was aimed to evaluate the efficacy and safety of patients with extensive SCLC treated with irinotecan/cisplatin (IP) versus EP. METHODS We searched EMBASE, PubMed, the Cochrane Library, China journal full-text database (CJFD), Chinese scientific journal full-text database (CSJD), Chinese biomedicine literature database (CBM) for randomized controlled trials comparing IP with EP regimens. Two reviewers independently assessed the quality of included studies and extracted data. We analyzed the data using Review Manager (version 5.0). RESULTS Four randomized controlled trials totaling 1 180 patients were included. The results of meta analysis were as follows: there was no significant difference between IP regimen and EP regimens in one year survive rate (RR=1.22, 95%CI: 0.97-1.54), two year survive rate (RR=2.26, 95%CI: 0.46-11.21). There was significant difference between IP regimen and EP regimens in overall response rate (RR=1.13, 95%CI: 1.03-1.25), grade 3/4 neutropenia (RR=0.48, 95%CI: 0.34-0.69), thrombopenia (RR=0.23, 95%CI: 0.15-0.36), grade 3 anemia (RR=0.55, 95%CI: 0.40-0.77), grade 3/4 diarrhea (RR=9.56, 95%CI: 4.91-18.59), grade 3 nausea/vomiting (RR=1.70, 95%CI: 1.19-2.43). CONCLUSIONS There is no significant difference between IP group and EP group with regard to one year survive rate, two year survive rate, but IP regimen improves reponse rate. IP regimen has less hematologic & greater gastrointestinal toxicity compared with EP, EP regimen remain the main standard chemotherapy in the treatment extensive small cell lung cancer due to cheapness, they still need to be confirmed by randomized controlled trials. |
| Starting Page | 1669 |
| Ending Page | 1677 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.lungca.org/index.php?journal=01&op=download&page=article&path%5B%5D=10.3779/j.issn.1009-3419.2009.08.010&path%5B%5D=988 |
| PubMed reference number | 20719176v1 |
| Alternate Webpage(s) | https://doi.org/10.3779/j.issn.1009-3419.2009.08.10 |
| DOI | 10.3779/j.issn.1009-3419.2009.08.10 |
| Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer |
| Volume Number | 12 |
| Issue Number | 8 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Anemia Biomedicine Cisplatin Cytarabine-Daunorubicin Regimen Diarrhea Etoposide Extraction Gastrointestinal Diseases Hematology (discipline) Neutropenia Non-Small Cell Lung Carcinoma Patients Postoperative Nausea and Vomiting Small cell carcinoma of lung Thrombocytopenia Traditional Chinese Medicine extensive stage small cell lung cancer irinotecan stage II bladder cancer |
| Content Type | Text |
| Resource Type | Article |
